Literature DB >> 9799734

High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.

A Suzuki1, J L de la Pompa, V Stambolic, A J Elia, T Sasaki, I del Barco Barrantes, A Ho, A Wakeham, A Itie, W Khoo, M Fukumoto, T W Mak.   

Abstract

BACKGROUND: Germ-line and sporadic mutations in the tumor suppressor gene PTEN (also known as MMAC or TEP1), which encodes a dual-specificity phosphatase, cause a variety of cancers such as Cowden disease, glioblastoma, endometrial carcinoma and prostatic cancer. PTEN is widely expressed, and Cowden disease consistently affects various organ systems, suggesting that the PTEN protein must have an important, although as yet poorly understood, function in cellular physiology.
RESULTS: Homozygous mutant mice lacking exons 3-5 of the PTEN gene (mPTEN3-5) had severely expanded and abnormally patterned cephalic and caudal regions at day 8.5 of gestation. Embryonic death occurred by day 9.5 and was associated with defective chorio-allantoic development. Heterozygous mPTEN3-5 mice had an increased incidence of tumors, especially T-cell lymphomas; gamma-irradiation reduced the time lapse of tumor formation. DNA analysis of these tumors revealed the deletion of the mPTEN gene due to loss of heterozygosity of the wild-type allele. Tumors associated with loss of heterozygosity in mPTEN showed elevated phosphorylation of protein kinase B (PKB, also known as Akt kinase), thus providing a functional connection between mPTEN and a murine proto-oncogene (c-Akt) involved in the development of lymphomas.
CONCLUSIONS: The mPTEN gene is fundamental for embryonic development in mice, as mPTEN3-5 mutant embryos died by day 9.5 of gestation, with patterning defects in cephalic and caudal regions and defective placentation. Heterozygous mice developed lymphomas associated with loss of heterozygosity of the wild-type mPTEN allele, and tumor appearance was accelerated by gamma-irradiation. These lymphomas had high levels of activated Akt/PKB, the protein product of a murine proto-oncogene with anti-apoptotic function, associated with thymic lymphomas. This suggests that tumors associated with mPTEN loss of heterozygosity may arise as a consequence of an acquired survival advantage. We provide direct evidence of the role of mPTEN as a tumor suppressor gene in mice, and establish the mPTEN mutant mouse as an experimental model for investigating the role of PTEN in cancer progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9799734     DOI: 10.1016/s0960-9822(07)00488-5

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  271 in total

1.  Phosphorylation of the PTEN tail regulates protein stability and function.

Authors:  F Vazquez; S Ramaswamy; N Nakamura; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

2.  A role for nuclear PTEN in neuronal differentiation.

Authors:  M B Lachyankar; N Sultana; C M Schonhoff; P Mitra; W Poluha; S Lambert; P J Quesenberry; N S Litofsky; L D Recht; R Nabi; S J Miller; S Ohta; B G Neel; A H Ross
Journal:  J Neurosci       Date:  2000-02-15       Impact factor: 6.167

3.  Pten, a protean tumor suppressor.

Authors:  G L Mutter
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Authors:  Lizhi He; Alistair Ingram; Adrian P Rybak; Damu Tang
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

5.  PTEN induces apoptosis and cavitation via HIF-2-dependent Bnip3 upregulation during epithelial lumen formation.

Authors:  Y Qi; J Liu; S Saadat; X Tian; Y Han; G-H Fong; P P Pandolfi; L Y Lee; S Li
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

Review 6.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

7.  PTEN controls tumor-induced angiogenesis.

Authors:  S Wen; J Stolarov; M P Myers; J D Su; M H Wigler; N K Tonks; D L Durden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

8.  Systemic elevation of PTEN induces a tumor-suppressive metabolic state.

Authors:  Isabel Garcia-Cao; Min Sup Song; Robin M Hobbs; Gaelle Laurent; Carlotta Giorgi; Vincent C J de Boer; Dimitrios Anastasiou; Keisuke Ito; Atsuo T Sasaki; Lucia Rameh; Arkaitz Carracedo; Matthew G Vander Heiden; Lewis C Cantley; Paolo Pinton; Marcia C Haigis; Pier Paolo Pandolfi
Journal:  Cell       Date:  2012-03-06       Impact factor: 41.582

Review 9.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

10.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

Authors:  K Podsypanina; L H Ellenson; A Nemes; J Gu; M Tamura; K M Yamada; C Cordon-Cardo; G Catoretti; P E Fisher; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.